NG2-PG in tumor vascularization and progression
NG2-PG in tumor vascularization and progression
批准号:
8193732
负责人:
William B. Stallcup
金额:
$42.74万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-01 至 2016-04-30
关键词:
AblationAdipocytesAffectAllograftingBasal laminaBlood CirculationBlood VesselsBone Marrow TransplantationBreast Cancer TreatmentCSPG4 geneCell CommunicationCell MaturationCell physiologyCellsCoculture TechniquesCultured Tumor CellsElementsEndothelial CellsExtravasationFatty acid glycerol estersGeneticGrowthHypoxiaIn VitroInvadedKnockout MiceLabelLungMammary NeoplasmsMammary glandMetastatic Neoplasm to the LungModelingMouse Mammary Tumor VirusMusMyelogenousMyeloid CellsNG2 antigenNeoplasm MetastasisPericytesPopulationProcessPropertyProteoglycanRadiation therapyRegimenResistanceRoleSiteStagingStromal CellsTherapeuticTransgenic MiceVascularizationWorkcancer therapycell assemblycell typein vitro Modelin vivointerestintravenous injectionmacrophagemalignant breast neoplasmmetastatic processmouse modelneoplastic celloffspringtumortumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The NG2 proteoglycan is not expressed by mammary tumor cells in the MMTV-PyMT mouse model of breast cancer, but is expressed by at least three important cell types in the tumor stroma: pericytes in the tumor vasculature, myeloid cells that invade the tumors from the circulation, and adipocytes in the mammary fat pad. By several criteria, including tumor latency, growth rate, and metastasis, ablation of NG2 greatly slows mammary tumor progression in the MMTV-PyMT model, emphasizing the power of microenvironmental factors in promoting tumorigenesis. Due to our interest in tumor vascularization and metastasis, we are focusing on mechanisms by which NG2 supports the tumor-promoting activities of pericytes and myeloid cells. The specific aims of this proposal will be to examine the respective effects of pericyte NG2 and myeloid cell NG2 on mammary tumor progression in the MMTV-PyMT model. For these purposes we will utilize cell type-specific ablations of NG2 in these two populations to analyze the progression of both spontaneous and allografted mammary tumors. In Aim 1 we will compare tumor progression and tumor vascularization in control mice and in pericyte-specific NG2 null mice produced by crossing NG2 floxed mice with Pdgfrb/Cre transgenic mice. Characterization of the tumor vasculature will include determinations of pericyte ensheathment of endothelial cells, maturation of pericytes and endothelial cells, assembly of the basal lamina, vessel patency, vessel leakiness, and tumor hypoxia. In vitro co-cultures of pericytes and endothelial cells will be used to further elucidate mechanisms by which NG2 supports pericyte/endothelial cell crosstalk. In Aim 2 we will compare myeloid cell function in control mice and in myeloid-specific NG2 null mice produced by crossing NG2 floxed mice with LysM/Cre transgenic mice. Characterization of the effects of NG2 ablation will include determination of M1 versus M2 polarization, assessment of changes in the size and differentiation state of key myeloid populations, and localization of these populations to critical sites such as vasculature and tumor margins. In vitro co-cultures of tumor cells and macrophages will be used to explore mechanisms by which NG2 affects macrophage/tumor cell interaction. In Aim 3 we will use both the pericyte-specific and myeloid-specific NG2 null mice to study the importance of NG2 in mammary tumor metastasis to the lungs. We will use fluorescent-labeled mammary tumor cells to dissect the metastatic process into its component stages, including intravasation of tumor cells into the vasculature, extravasation of tumor cells from the vasculature into the lungs, and establishment of pre-metastatic niches in the lungs.
PUBLIC HEALTH RELEVANCE: Improvements in the treatment of breast cancer will require a better understanding of tumor-promoting factors associated with both the mammary tumor cells themselves and the host stroma in which the tumors reside. The NG2 proteoglycan is present on two stromal cell types, microvascular pericytes and tumor myeloid cells, that promote mammary tumor progression by supporting tumor vascularization and metastasis. Our studies on the role of NG2 in stimulating the tumor-promoting activities of these cells will enhance our understanding of the vascularization and metastatic processes and will also identify the proteoglycan as a multifocal target for breast cancer therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ANIMAL RESOURCES
-
批准号:8378389
-
项目类别:
-
资助金额:$21.29万
-
财政年份:2012
-
负责人:William B. Stallcup
-
依托单位:
Oligodendrocyte Maturation/Myelination in NG2 Null Mice
-
批准号:8056780
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2010
-
负责人:William B. Stallcup
-
依托单位:
ANIMAL RESOURCES
-
批准号:8181800
-
项目类别:
-
资助金额:$11.82万
-
财政年份:2010
-
负责人:William B. Stallcup
-
依托单位:
Ephrin-A3 in Neuron-Glia Communication
-
批准号:7185423
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2006
-
负责人:William B. Stallcup
-
依托单位:
CORE--Shared Resources Animal Facility
-
批准号:6990463
-
项目类别:
-
资助金额:$6.51万
-
财政年份:2004
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:6622932
-
项目类别:
-
资助金额:$51.7万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:7033823
-
项目类别:
-
资助金额:$43.02万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:7894844
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:8657813
-
项目类别:
-
资助金额:$42.33万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:9263044
-
项目类别:
-
资助金额:$6.1万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:6881044
-
项目类别:
-
资助金额:$44.06万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:7655659
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
Signaling mechanisms activated by engagement of NGE-PG
-
批准号:6583735
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:8298133
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:8462211
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:6709410
-
项目类别:
-
资助金额:$44.06万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
NG2-PG in tumor vascularization and progression
-
批准号:6459290
-
项目类别:
-
资助金额:$44.06万
-
财政年份:2002
-
负责人:William B. Stallcup
-
依托单位:
Signaling mechanisms activated by engagement of NGE-PG
-
批准号:6475023
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2001
-
负责人:William B. Stallcup
-
依托单位:
Signaling mechanisms activated by engagement of NGE-PG
-
批准号:6301949
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2000
-
负责人:William B. Stallcup
-
依托单位:
CORE--ANIMAL FACILITY
-
批准号:6102081
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1999
-
负责人:William B. Stallcup
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: